Astellas Pharma and Kate Therapeutics announced an exclusive licence agreement for the development and commercialisation of KT430. Under the terms of the agreement, Astellas will provide an upfront payment to Kate Therapeutics. Additionally, Kate Therapeutics stands to receive milestone payments related to development, regulatory approvals, and commercial achievements, along with royalties based on global sales. As part of the agreement, Astellas will gain exclusive worldwide rights to develop, manufacture, and market KT430. This agreement between Astellas and Kate Therapeutics aims to explore and advance the development of KT430 as a potential therapy for individuals diagnosed with X-linked myotubular myopathy (XLMTM). Moreover, this will allow Astellas and Kate Therapeutics to combine the expertise and resources to evaluate the therapeutic potential of KT430 in addressing the specific challenges faced by XLMTM patients. KT430 is a preclinical next-generation investigational gene therapy that aims to treat X-linked myotubular myopathy (XLMTM). XLMTM is indeed a serious, life-threatening, and rare neuromuscular disease characterised by extreme muscle weakness, respiratory failure, and an increased risk of early death.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!